Fig. 3From: Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritisDMARD treatment (predicted marginal means) during the first year for the three responder groups: A Methotrexate (MTX) Dose (in milligram, mg of weekly dosing) B Leflunomide Use (proportion of patients)Back to article page